Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine

The American Journal of Cardiology

Volumn 73, Issue 5, 1994, Pages 346-352

  Pratt, Craig M ^a,b,c,d   Hertz, Robin P ^a,b,c,d   Ellis, Bruce E ^a,b,c,d   Crowell, Steven P ^a,b,c,d   Louv, William ^a,b,c,d   Moyé, Lemuel ^a,b,c,d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c Marion Merrell Dow Inc   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BROMPHENIRAMINE; CHLORPHENIRAMINE; CLEMASTINE; CLEMASTINE FUMARATE; DIPHENHYDRAMINE; ERYTHROMYCIN; IBUPROFEN; KETOCONAZOLE; NON PRESCRIPTION DRUG; TERFENADINE; TRIPROLIDINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; COHORT ANALYSIS; DRUG EXPOSURE; FEMALE; HEART ARREST; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAID; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; SUDDEN DEATH;

ADULT; AGE FACTORS; AGED; ARRHYTHMIA; CLEMASTINE; COHORT STUDIES; COMPARATIVE STUDY; DEATH, SUDDEN, CARDIAC; DISEASE; DRUG THERAPY; DRUGS, NON-PRESCRIPTION; FEMALE; HEART ARREST; HUMAN; IBUPROFEN; INFORMATION SYSTEMS; MALE; MIDDLE AGE; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; TERFENADINE; VENTRICULAR FUNCTION;

EID: 0028082462     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9149(94)90006-X     Document Type: Article

References (21)

1. Torsades de pointes occurring in association with terfenadine use (ltr)
2. Torsades de pointes after treatment with terfenadine and ketoconazole
3. Severe intoxication with antihistamines complicated by ventricular tachycardia
4. Torsades de Pointes Occurring in Association With Terfenadine Use
5. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences
6. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin
7. The importance of adverse reaction reporting by physicians
8. Use of automated databases for pharmacoepidemiology research
9. 1980 to 1990 English language bibliography of pharmacoepidemiologic research using computerized administrative databases
10. A compendium of public health data sources
11. Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial Infarction
12. Effect of the Antiarrhythmic Agent Moricizine on Survival after Myocardial Infarction
13. Clinical and regulatory implications of the Cardiac Arrhythmia Suppression Trial (CAST)
14. The Cardiac Arrhythmia Suppression Trial: background, interim results and implications
15. Prevalence and characteristics of proarrhythmia from moricizine (ethmozine)
16. The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio
17. Torsade de pointes due to quinidine: observations in 31 patients
18. QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards
19. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis